Anti-TNF therapy in the injured spinal cord

Trends in Pharmacological Sciences

Volumn 32, Issue 2, 2011, Pages 107-115

  Esposito, Emanuela ^a   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CERTOLIZUMAB PEGOL; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; ROLIPRAM; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLODYNIA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; BURSITIS; CHOLECYSTITIS; CHRONIC INFLAMMATION; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE RELEASE; DEPRESSION; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG STRUCTURE; DYSPHAGIA; DYSPNEA; FACE EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND EDEMA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEPROSY; LUPUS LIKE SYNDROME; LYMPHOMA; MORNING SICKNESS; MULTIPLE MYELOMA; MYALGIA; NEOPLASM; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; SPINAL CORD INJURY; SYNAPTIC TRANSMISSION; SYSTEMIC MYCOSIS; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTEBRA FRACTURE;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; SPINAL CORD INJURIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79651468735     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.11.009     Document Type: Review

References (75)

1. National Spinal Cord Injury Statistical Center (2005) Spinal cord injury. Facts and figures at a glance. J. Spinal Cord. Med. 28, 379-380
2. A. Varma Predictors of early mortality after traumatic spinal cord injury: a population-based study Spine (Phila Pa 1976) 35 2010 778 783
3. M.M. Priebe Spinal cord injury medicine. 6. Economic and societal issues in spinal cord injury Arch. Phys. Med. Rehabil. 88 2007 S84 S88
4. G. Onose A review of published reports on neuroprotection in spinal cord injury Spinal Cord 47 2009 716 726
5. R.J. Hurlbert Strategies of medical intervention in the management of acute spinal cord injury Spine (Phila Pa 1976) 31 2006 S16 S21 discussion S36
6. E.D. Hall, and J.E. Springer Neuroprotection and acute spinal cord injury: a reappraisal NeuroRx 1 2004 80 100 (Pubitemid 46589342)
7. T. Inukai Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twy/twy) sustaining chronic mechanical compression Spine (Phila Pa 1976) 34 2009 2848 2857
8. C.H. Tator, and M.G. Fehlings Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms J. Neurosurg. 75 1991 15 26
9. L. Yang Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury Spine (Phila Pa 1976) 29 2004 966 971 (Pubitemid 38580232)
10. P. Yan Cellular localization of tumor necrosis factor-alpha following acute spinal cord injury in adult rats J. Neurotrauma 18 2001 563 568 (Pubitemid 32472846)
11. S.M. Lucas The role of inflammation in CNS injury and disease Br. J. Pharmacol. 147 Suppl. 1 2006 S232 S240
12. J.R. Bethea Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats J. Neurotrauma 16 1999 851 863 (Pubitemid 29491758)
13. C. Profyris Degenerative and regenerative mechanisms governing spinal cord injury Neurobiol. Dis. 15 2004 415 436 (Pubitemid 38429958)
14. J. Glaser Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury J. Neurosci. Res. 77 2004 701 708 (Pubitemid 39194611)
15. A. Trivedi Inflammation and spinal cord injury: infiltrating leukocytes as determinants of injury and repair processes Clin. Neurosci. Res. 6 2006 283 292 (Pubitemid 44849178)
16. Y.H. Ahn Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival Biochem. Biophys. Res. Commun. 348 2006 560 570 (Pubitemid 44188602)
17. P. Gal Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review Cell Mol. Neurobiol. 29 2009 1025 1035
18. A.P. Amar, and M.L. Levy Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury Neurosurgery 44 1999 1027 1039 discussion 1039-1040
19. M.E. Schwab, and D. Bartholdi Degeneration and regeneration of axons in the lesioned spinal cord Physiol. Rev. 76 1996 319 370 (Pubitemid 26163712)
20. L. Leung, and C.M. Cahill TNF-alpha and neuropathic pain - a review J. Neuroinflammation 7 2010 27 38
21. P. Vandenabeele Two tumour necrosis factor receptors: structure and function Trends Cell Biol. 5 1995 392 399
22. I.S. Grewal Overview of TNF superfamily: a chest full of potential therapeutic targets Adv. Exp. Med. Biol. 647 2009 1 7
23. E. Esposito, and S. Cuzzocrea TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma Curr. Med. Chem. 16 2009 3152 3167
24. S.J. Choi Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes Yonsei Med. J. 46 2005 818 826 (Pubitemid 43085186)
25. L.A. Tartaglia The two different receptors for tumor necrosis factor mediate distinct cellular responses Proc. Natl. Acad. Sci. U. S. A. 88 1991 9292 9296 (Pubitemid 21915617)
26. K.J. Tracey, and A. Cerami Metabolic responses to cachectin/TNF. A brief review Ann. N. Y. Acad. Sci. 587 1990 325 331 (Pubitemid 20249304)
27. M. Zerey Minimally invasive management of colon cancer Surg. Innov. 13 2006 5 15 (Pubitemid 43826957)
28. E. Dharmana Divergent effects of tumor necrosis factor-alpha and lymphotoxin-alpha on lethal endotoxemia and infection with live Salmonella typhimurium in mice Eur. Cytokine Netw. 13 2002 104 109 (Pubitemid 34535579)
29. M. Dinomais Significant recovery of motor function in a patient with complete T7 paraplegia receiving etanercept J. Rehabil. Med. 41 2009 286 288
30. A.M. Feldman TNF alpha-still a therapeutic target Clin. Transl. Sci. 1 2008 145
31. G. Stoll Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system Adv. Exp. Med. Biol. 513 2002 87 113 (Pubitemid 36332404)
32. T. Oshima TNF-alpha contributes to axonal sprouting and functional recovery following traumatic brain injury Brain Res. 1290 2009 102 110
33. Y. Kawasaki Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord J. Neurosci. 28 2008 5189 5194
34. Y. Fong Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins Am. J. Physiol. 256 1989 R659 665
35. R. Goldbach-Mansky Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition N. Engl. J. Med. 355 2006 581 592 (Pubitemid 44200651)
36. C.A. Dinarello Immunological and inflammatory functions of the interleukin-1 family Annu. Rev. Immunol. 27 2009 519 550
37. N. Drojdahl Dynamics of oligodendrocyte responses to anterograde axonal (Wallerian) and terminal degeneration in normal and TNF-transgenic mice J. Neurosci. Res. 75 2004 203 217 (Pubitemid 38049391)
38. L. Bernardino Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures J. Neurosci. 25 2005 6734 6744 (Pubitemid 41023141)
39. P. Yan Expression of the type 1 and type 2 receptors for tumor necrosis factor after traumatic spinal cord injury in adult rats Exp. Neurol. 183 2003 286 297 (Pubitemid 37205071)
40. G.M. Kim Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury J. Neurosci. 21 2001 6617 6625
41. I. Klusman, and M.E. Schwab Effects of pro-inflammatory cytokines in experimental spinal cord injury Brain Res. 762 1997 173 184 (Pubitemid 27315947)
42. P.P. Sfikakis The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions Curr. Dir. Autoimmun. 11 2010 180 210
43. A. Nesbitt Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm. Bowel Dis. 13 2007 1323 1332 (Pubitemid 350206841)
44. M.P. Karampetsou TNF-α antagonists beyond approved indications: stories of success and prospects for the future QJM 103 2010 917 928
45. F. Licastro Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules Int. J. Immunopathol. Pharmacol. 22 2009 567 572
46. D.K. Podolsky Inflammatory bowel disease N. Engl. J. Med. 347 2002 417 429 (Pubitemid 34851835)
47. S. Mpofu Anti-TNF-alpha therapies: they are all the same (aren't they?) Rheumatology (Oxford) 44 2005 271 273 (Pubitemid 40361279)
48. L. Wimett TNF-alpha inhibitors offer hope to RA patients Nurse Pract. 28 2003 40 48
49. G. Kurt Neuroprotective effects of infliximab in experimental spinal cord injury Surg. Neurol. 71 2009 332 336 discussion 336
50. J. Jin Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis Acta Pharmacol. Sin. 31 2010 1133 1140
51. K. Kato Immediate anti-tumor necrosis factor-alpha (etanercept) therapy enhances axonal regeneration after sciatic nerve crush J. Neurosci. Res. 88 2010 360 368
52. E. Tobinick Perispinal etanercept: a new therapeutic paradigm in neurology Expert Rev. Neurother. 10 2010 985 1002
53. T. Genovese Immunomodulatory effects of etanercept in an experimental model of spinal cord injury J. Pharmacol. Exp. Ther. 316 2006 1006 1016 (Pubitemid 43345272)
54. T. Genovese Combination of dexamethasone and etanercept reduces secondary damage in experimental spinal cord trauma Neuroscience 150 2007 168 181 (Pubitemid 350214494)
55. S. Sweitzer Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain Neuroscience 103 2001 529 539 (Pubitemid 32201938)
56. C.I. Svensson Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38 Neurosci. Lett. 379 2005 209 213 (Pubitemid 40544536)
57. R. Fernandez-Botran Soluble cytokine receptors in biological therapy Expert Opin. Biol. Ther. 2 2002 585 605
58. D. Yocum Effective use of TNF antagonists Arthritis Res. Ther. 6 Suppl. 2 2004 S24 30
59. J. Ducharme The safety of infliximab infusions in the community setting Can. J. Gastroenterol. 24 2010 307 311
60. C. Ferraro-Peyret Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study Arthritis Res. Ther. 6 2004 R535 543
61. P. Balakumar, and M. Singh Anti-tumour necrosis factor-alpha therapy in heart failure: future directions Basic Clin. Pharmacol. Toxicol. 99 2006 391 397 (Pubitemid 44813905)
62. J.B. De Sanctis Pharmacological properties of thalidomide and its analogues Recent Pat. Inflamm. Allergy Drug Discov. 4 2010 144 148
63. M.A. Palladino Anti-TNF-alpha therapies: the next generation Nat. Rev. Drug Discov. 2 2003 736 746
64. G.B. Gordon Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite Proc. Natl. Acad. Sci. U. S. A. 78 1981 2545 2548 (Pubitemid 11119864)
65. K. Yasui Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation Curr. Pharm. Des. 11 2005 395 401 (Pubitemid 40277865)
66. J. Fujita Thalidomide and its analogues inhibit lipopolysaccharide- mediated Iinduction of cyclooxygenase-2 Clin. Cancer Res. 7 2001 3349 3355 (Pubitemid 33069965)
67. C.A. Dinarello Anti-inflammatory agents: present and future Cell 140 2010 935 950
68. S. Kuwabara Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome J. Neurol. Neurosurg. Psychiatry 79 2008 1255 1257
69. L.G. Corral Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J. Immunol. 163 1999 380 386 (Pubitemid 29295864)
70. S. Majumdar Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester J. Immunol. 168 2002 2644 2651 (Pubitemid 34211639)
71. B. Settles Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide Cell Mol. Biol. (Noisy-le-grand) 47 2001 1105 1114
72. T. Genovese Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma Shock 30 2008 231 240
73. G.C. Koopmans Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury Exp. Neurol. 216 2009 490 498
74. C.J. Lee The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model Spinal Cord 45 2007 149 157
75. G. Zara Thalidomide and sensory neurotoxicity: a neurophysiological study J. Neurol. Neurosurg. Psychiatry 79 2008 1258 1261